Trials / Completed
CompletedNCT00629213
Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial
Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,429 (planned)
- Sponsor
- GWT-TUD GmbH · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study was to analyse the independent and joint effects of the components of the metabolic syndrome (MetS) on the incidence of diabetes in people with impaired glucose tolerance (IGT) and to assess the effect of acarbose by MetS status. Double-blind placebo controlled trial, 1,368 patients, follow-up time 3.3 years. MetS by ATP III definition with fasting plasma glucose of ≥ 6.1 mmol/l as limit for impaired fasting glucose (IFG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acarbose | |
| DRUG | placebo |
Timeline
- First posted
- 2008-03-05
- Last updated
- 2008-03-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00629213. Inclusion in this directory is not an endorsement.